CRNX (Crinetics Pharmaceuticals, Inc.) Stock Analysis - Community

Crinetics Pharmaceuticals, Inc. (CRNX) is a publicly traded Healthcare sector company. As of May 21, 2026, CRNX trades at $36.28 with a market cap of $3.66B and a P/E ratio of -7.30. CRNX moved +3.84% today. Year to date, CRNX is -24.72%; over the trailing twelve months it is +15.62%. Its 52-week range spans $24.10 to $62.53. Analyst consensus is strong buy with an average price target of $86.00. Rallies surfaces CRNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

How does the Rallies community trade CRNX?

Rallies community data for CRNX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.

CRNX Key Metrics

Key financial metrics for CRNX
MetricValue
Price$36.28
Market Cap$3.66B
P/E Ratio-7.30
EPS$-4.95
Dividend Yield0.00%
52-Week High$62.53
52-Week Low$24.10
Volume581.00K
Avg Volume0
Revenue (TTM)$7.70M
Net Income$-465.32M
Gross Margin86.02%

Latest CRNX News

Recent CRNX Insider Trades

  • Knight Jeff E. sold 85.16K (~$3.42M) on Apr 8, 2026.
  • Knight Jeff E. sold 5.95K (~$220.80K) on Mar 16, 2026.
  • Knight Jeff E. sold 3.96K (~$149.61K) on Mar 16, 2026.

CRNX Analyst Consensus

10 analysts cover CRNX: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $86.00.

Common questions about CRNX

How does the Rallies community trade CRNX?
Rallies community data for CRNX shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
Does Rallies show retail investor data for CRNX?
Rallies shows anonymized community ownership, retail positioning, sentiment, and portfolio context for CRNX when enough community data is available.
Is CRNX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CRNX. It does not provide personalized investment advice.
CRNX

CRNX